US OptionsDetailed Quotes
VSTM241220C9000
- 0.10
- 0.000.00%
15min DelayClose Nov 22 15:59 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume9 Open Interest9.00Strike Price0.00Turnover207.38%IV127.50%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1156Delta0.0887Gamma40.00Leverage Ratio-0.0083Theta0.0003Rho4.62Eff Leverage0.0021Vega
Verastem Stock Discussion
Pretty damn good run so far. I only managed to hop on in Sept.
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumabPatients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months)...
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response ...
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/G...
No comment yet